Literature DB >> 23645520

New anti-rebate legislation in South Korea.

Su-Yeon Yu1, Bong-Min Yang, Jin-Hyun Kim.   

Abstract

The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for receiving illegal kickbacks from drug companies. Previously, provision of illegal kickbacks by drug companies led to criminal punishment of the drug companies alone, leaving doctors and pharmacists unpunished as the recipients. With the introduction of the "Dual Punishment System (DPS)" reform, criminal punishment for illegal rebates is extended to those receiving illegal kickbacks. Although bitter controversy erupted among stakeholders when the reform was first drafted, a civic group participated in the reform process and effectively influenced the legislative process to a successful end. Some interim outcomes from the DPS in terms of bringing illegal practices to account have already been reported since the policy's implementation in November 2010. The reform background, goals, potential issues, and policy implications are explored in this study with the objective of providing further insight into drug policy for other countries that face similar challenges in the area of drug marketing.

Mesh:

Substances:

Year:  2013        PMID: 23645520     DOI: 10.1007/s40258-013-0029-x

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  1 in total

1.  Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.

Authors:  Ki-Bong Yoo; Sang Gyu Lee; Sohee Park; Tae Hyun Kim; Jeonghoon Ahn; Mee-Hyun Cho; Eun-Cheol Park
Journal:  BMJ Open       Date:  2015-07-15       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.